Immunic Inc.

NASDAQ: IMUX · Real-Time Price · USD
1.17
0.18 (18.17%)
At close: May 01, 2025, 3:59 PM
1.15
-1.71%
After-hours: May 01, 2025, 06:04 PM EDT
18.17%
Bid 1.14
Market Cap 112.11M
Revenue (ttm) n/a
Net Income (ttm) -100.51M
EPS (ttm) -1
PE Ratio (ttm) -1.17
Forward PE -1.38
Analyst Buy
Ask 1.17
Volume 2,271,926
Avg. Volume (20D) 840,618
Open 1.02
Previous Close 0.99
Day's Range 1.01 - 1.19
52-Week Range 0.83 - 2.11
Beta 1.92

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 17, 2014
Employees 91
Stock Exchange NASDAQ
Ticker Symbol IMUX
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 1053.85% from the latest price.

Stock Forecasts
2 days ago
-22.65%
Immunic shares are trading lower. The company repo... Unlock content with Pro Subscription
2 months ago
+12.38%
Immunic shares are trading higher after the company announced its ORAL IMU-856 demonstrated a dose-dependent increase of GLP-1 in celiac disease patients.